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ABSTRACT: A method has been developed for release/
isolation of O-glycans from glycoproteins in whole cell lysates
for mass spectrometric analysis. Cells are lysed in SDS, which
is then exchanged for urea and ammonium bicarbonate in a
centrifugal ﬁlter, before treating with NH4OH to release O-
glycans. Following centrifugation, O-glycans are recovered in
the ﬁltrate. Sonication achieves O-glycan release in 1 h.
Combining the established protocol for ﬁlter-aided N-glycan
separation, here optimized for enhanced PNGase F eﬃciency,
with the developed O-glycan release method allows analysis of
both N- and O-glycans from one sample, in the same ﬁlter
unit, from 0.5 to 1 million cells. The method is compatible with subsequent analysis of the residual protein by liquid
chromatography−mass spectrometry (LC−MS) after glycan release. The medium throughput approach is amenable to analysis
of biological replicates, oﬀering a simple way to assess the often subtle changes to glycan proﬁles accompanying diﬀerentiation
and disease progression, in a statistically robust way.
Glycans, carbohydrate chains glycosidically linked toproteins and lipids, coat all cell surfaces and play a
central role in cellular and physiological processes such as
protein targeting and immune modulation. Glycans also play
important roles in disease. Alterations in glycosylation have
been observed in cancers,1 Alzheimer’s disease2,3 inﬂammatory
conditions4 and in congenital disorders of glycosylation
(CDGs). CDGs are a large class of rare genetic diseases in
which alterations in various forms of glycosylation cause a
variety of systemic pathologies.5−8 Protein glycosylation is also
a major consideration in the pharmaceutical industry, as
glycoproteins are used in a multitude of therapeutic
applications, including therapeutic monoclonal antibodies9,10
and vaccines.11−14 The exact nature of glycans present on
therapeutic glycoproteins is critical, inﬂuencing eﬃcacy,
immunogenicity,15−17 stability18,19 and pharmacokinetics.20,21
Glycans are important as drug targets.22 It is therefore
important to understand glycan biosynthesis and to have
convenient methods to assess glycan structures, in order to help
further understand disease and genetic disorders linked to
errors in glycosylation, to potentially help in both disease
diagnostics and in development of biotherapeutics.
The biosynthetic code for glycans remains enigmatic because,
unlike protein and nucleic acid biosynthesis, there is no
template for glycan biosynthesis. Eukaryotic glycan biosynthesis
is managed by a large number of glycosyltransferase and
glycosidase enzymes (located in the endoplasmic reticulum
(ER) and the Golgi apparatus) and is dependent on their
expression levels, location, and activity. These can change in
response to alterations in the cell’s environment, diﬀerentiation
or proliferation state, or as a consequence of intercellular
communication. Consequently, the overall distribution of
glycan structures, and hence the glycan proﬁles, can vary
quite signiﬁcantly depending on the tissue in which they are
expressed as well as local conditions, making analysis of
protein-linked glycan structures both challenging and impor-
tant. As structures cannot be predicted from a template, they
have to be determined experimentally in each distinct case. To
determine which of the changes in glycan proﬁles are
signiﬁcant, and which changes are just the eﬀects of biological
variation, analysis of multiple biological samples in parallel is
needed. It is not necessary to carry out ultimate deep glycan
proﬁling to make this assessment, but rather to uncover overall
shifts in relative glycan proportions. This makes it possible to
avoid the use of very large numbers of cells that would be
necessary for deep proﬁling, but that at the same time limit the
feasibility of analyzing appropriate replicates.23,24
Enzymes and biosynthetic pathways leading to N- and O-
protein glycosylation have been deﬁned25−27 in a variety of
experimental systems, enabling understanding of the range of
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possible glycan structures of both glycosylation types. While we
have an idea of the glycan structures expected, the
consequences of the loss of even a single enzyme are not
always trivial to predict. Much more diﬃcult, if possible at all, is
to predict consequences of glycan biosynthetic enzyme
mislocalization within the Golgi. There have been a number
of studies into how enzyme localization inﬂuences glycan
processing in the Golgi. It is clear that enzymes are sorted using
transport vesicles, which are targeted to their appropriate
locations during the vesicle tethering process. This is mediated
by the conserved oligomeric Golgi (COG) protein complex,
which has been shown to play a central role in maintaining the
ﬁdelity of glycosylation in all eukaryotic cells.28−31
Glycomic workﬂows frequently use separate protocols and/
or large quantities of sample/cells32,33 to be able to look at both
N- and O-glycans and for proteomic studies. Since some
genetic diseases can occur as a result of a genetic defect that
aﬀects N- and O-glycosylation simultaneously, whereas some
defects only aﬀect one glycan type, analysis of both N- and O-
glycans from the same sample in an integrated protocol is ideal.
Such a one-sample-one-pot method has the advantage of
reducing the amount of material needed to carry out such
studies and oﬀers the potential, after N- and O-glycan release,
to analyze the remaining protein, enabling a complementary
proteomic comparison between samples. Recently, a method
named ﬁlter-aided N-glycan separation or FANGS, has been
developed for the release and isolation, using a centrifugal ﬁlter,
of N-glycans from glycoproteins solubilized from whole cell
lysates.34 FANGS is a simple protocol making use of ﬁlter-aided
sample preparation (FASP) for SDS removal, ﬁrst described by
Manza et al.35 and then by Wisńiewski et al.36 for exchange of
SDS with urea. In FANGS, following SDS removal, the
glycoprotein extract is incubated with PNGase F to release the
N-glycans. N-Glycans are collected after centrifugation. FANGS
has been successful using only 3.5 × 105 cells, equivalent to one
well of a six well culture plate and so is applicable to low cell
numbers and therefore can be used to analyze multiple samples
in parallel. Analogous methods are, however, still needed to
release and isolate O-glycans from cultured cells for mass
spectrometric analysis.
For O-glycosylation, there is no enzyme that shows a broad
speciﬁcity for O-glycan release to compare with PNGase F,37
and so chemical methods are the most appropriate for pan-
speciﬁc O-glycan release. Reductive β-elimination involving
treatment of the glycoprotein with NaOH and NaBH4 is one of
the best-established methods for releasing O-glycans from
glycoproteins.37 O-glycans can also be released by treating
glycoproteins with NH4OH which has the advantage of being
volatile and so is easily removed under reduced pressure.38
Conditions for releasing glycans from glycoproteins/peptides
generally involve overnight or longer incubation. There are
reports of using microwave assistance to speed up incubation
times in a range of chemical and enzymatic reactions. Both
domestic microwaves and microwave reactors have been used
to assist tryptic digestion of proteins as well as to release N-
glycans and O-glycans from puriﬁed glycoproteins such as
bovine fetuin and mucins in 20−120 min.39−42 Sonication, used
widely in industry and research, is also used to accelerate
reactions in organic synthesis, stimulate enzymes in enzymatic
synthesis, and is also used to disrupt cell membranes without
damaging the cell contents.43 However, there appears to be
nothing in the literature to suggest sonication has been assessed
for use in the release of glycoprotein glycans. Both microwave
irradiation and sonication have thus been investigated in this
study for their potential to speed up O-glycan release and
reduce sample preparation times.
Here we present a ﬁlter-based approach, making use of a
centrifugal ﬁlter to carry out O-glycan release using NH4OH as
well as exploiting advantages of an optimized FASP35,36
approach, eFASP,44 which uses alternative reagents to FASP.
We show how O-glycan release can be achieved in 1 h with the
aid of sonication, without loss of labile sialic acids, and giving
results comparable with those from the well-accepted overnight
incubation methods. A streamlined protocol is presented for a
one-sample-one-pot approach, to release both N- and O-
glycans (performed as N- then O-glycan release or vice versa)
from the same sample, in the same sample pot, by combining
an optimized FANGS protocol with the O-glycan release
method, also oﬀering the potential to subsequently analyze the
protein remaining in the ﬁlter. The method developed has been
demonstrated using the standard glycoprotein porcine stomach
mucin and has then been applied to the study of mesenchymal
stromal cells (MSCs), using only 0.5−1 million cells.
■ EXPERIMENTAL PROCEDURES
Fully detailed experimental procedures are described in the
Supporting Information.
Extraction of Glycoproteins from Porcine Bladder
Urothelial Tissue. Bladders were obtained from an abattoir (A
Traves & Son Ltd.) and processed the morning they were
collected. Urothelium was removed from lumen of dissected
bladders by scraping with a scalpel.
hTERT Mesenchymal Stromal Cell (MSC) Culture.
hTERT MSCs are immortalized cell lines generated from
primary human mesenchymal stromal cells by lentiviral
transduction with a human telomerase reverse transcriptase
gene and subsequent single cell cloning.45 Cells were cultured
in Dulbecco’s Modiﬁed Eagle Medium (high glucose, pyruvate,
no glutamine) supplemented with 10% fetal bovine serum, 1%
penicillin/streptomycin, and 1% Gluta-Max-I. Cultures were
grown in a humidiﬁed incubator at 37 °C in 5% CO2 in air in
10 cm Petri dishes and harvested at around 80% conﬂuency.
Optimized Method for Preparation of Glycoprotein
Standards, Urothelial Cell Samples, and MSCs for Glycan
Release. Porcine stomach mucin (Sigma-Aldrich, U.K.) was
solubilized in eFASP lysis buﬀer.44 For urothelial and MSC
samples, eFASP lysis buﬀer was added at 10× the cell pellet
volume. Samples were lysed, reduced, and alkylated as
described.44 Glycoprotein samples were then diluted with
exchange buﬀer (8 M urea, 100 mM ammonium bicarbonate)
in a 40:1 (v:v) ratio of exchange buﬀer to sample solution. The
sample solution was transferred to a ﬁlter unit (Amicon Ultra-
0.5 centrifugal ﬁlter unit, nominal mass cut oﬀ 30 kDa) and
centrifuged for 5 min, and the ﬁltrate discarded. The sample
retained above the ﬁlter membrane was rinsed three times with
300 μL of exchange buﬀer and 50 mM ammonium bicarbonate
(centrifuging after each rinse for 5 min), discarding the ﬁltrate.
The ﬁlter unit was transferred to a clean collection tube ready
for N- or O-glycan release.
Glycan Release. To release O-glycans, glycoproteins were
treated with 300 μL of NH4OH at 45 °C for 16 h, as
described,46,38 directly in the ﬁlter unit. Alternatively, on
treating with NH4OH, samples were sonicated, in the ﬁlter unit,
at 45 °C for 5 min then left in the water bath for 10 min to
avoid overheating, followed by another 5 min of sonication.
The sonication/rest cycle was repeated giving a total sonication
Analytical Chemistry Article
DOI: 10.1021/acs.analchem.7b00143
Anal. Chem. 2017, 89, 5840−5849
5841
time of 20 min and total intervening rest time of 40 min.
Following incubation, the ﬁlter device was centrifuged to collect
the O-glycans in the ﬁltrate. The O-glycan ﬁltrate was dried
using a vacuum centrifuge. N-Glycans were released as
described using FANGS.34 Glycans were permethylated prior
to mass spectrometric (MS) analysis and relative quantiﬁca-
tion.47
Tryptic Digestion. The protein remaining in the ﬁlter unit
following N- and O-glycan release was treated with trypsin at
37 °C for 16 h. Following incubation the ﬁlter was centrifuged
to collect the tryptic peptides. Samples were acidiﬁed with 0.1%
TFA before LC−MS/MS analysis.
Sodium Dodecyl Sulfate-Polyacrylamide Gel Electro-
phoresis (SDS-PAGE). RNase B samples were denatured by
heating at 95 °C for 5 min in the presence of 2% SDS. SDS-
PAGE was performed using discontinuous polyacrylamide gels
with a 12% separating gel layer in a standard Tris-glycine buﬀer.
Gels were electrophoresed at 180 V and stained with
Coomassie brilliant blue.
Glycan Analysis. Dried permethylated glycans were
dissolved in 10 μL of acetonitrile. (For relative quantitation
of glycans, samples were spiked with an internal standard,
deuteropermethylated maltotetraose.) Sample spots were
prepared by mixing matrix solution (20 mg/mL 2,5-
dihydrobenzoic acid in 50% aqueous acetonitrile) with sample
solution in a 2:1 (v:v) ratio. A volume of 2 μL of the mixture
was transferred to a MALDI target plate and dried under
vacuum. Mass spectra were acquired in positive ion mode on a
9.4 T solariX Fourier tranform ion cyclotron resonance mass
spectrometer (Bruker Daltonics), with a smartbeam-II laser.
Spectra were acquired using ftmscontrol 2.0 and processed with
DataAnalysis 4.0. Product ion spectra were acquired using a
Nanospray Flex ion source on an Orbitrap Fusion hybrid mass
spectrometer (Thermo Scientiﬁc). Positive ESI-MS and MS2
product ion spectra were acquired in the Orbitrap using
Xcalibur 4.0 software (Thermo Scientiﬁc). Fragmentation was
induced using either collision induced dissociation or higher
energy collision dissociation.
Peptide Analysis. Samples were loaded onto an UltiMate
3000 RSLCnano HPLC system (Thermo Scientiﬁc) equipped
with a PepMap 100 Å C18, 5 μm trap column (300 μm × 5 mm
Thermo Scientiﬁc) and an Acclaim PepMap RSLC, 2 μm, 100
Å, C18 RSLC nanocapillary column (75 μm × 150 mm,
Thermo Scientiﬁc). The nanoLC system was interfaced with an
Orbitrap Fusion hybrid mass spectrometer with a Nanospray
Flex ionization source. Positive ESI-MS and MS2 product ion
spectra were acquired. Peak lists were generated using Mascot
Distiller (version 5, Matrix Science). MGF ﬁles were searched
against the porcine subset of the UniProt database (34 316
sequences; 14 316 901 residues), with a decoy database, using a
locally running copy of the Mascot program (Matrix Science
Ltd., version 2.5.1).
■ RESULTS AND DISCUSSION
A method has been developed, based on FANGS, to release
and isolate O-glycans from glycoproteins for MS analysis. The
method makes use of a centrifugal ﬁlter as a simple reaction
vessel in which glycoproteins can be treated with NH4OH
solution to release O-glycans by β-elimination. Following
centrifugation, glycans are retrieved in the ﬁltrate, as they pass
through the ﬁlter membrane while proteins are large enough to
be retained above the membrane. Isolated O-glycans are
permethylated for MS analysis. The method can be
conveniently combined with the established FANGS protocol,
to release, isolate, and analyze both N- and O-glycans using one
sample, in the same ﬁlter unit, enabling analysis of the whole
glycome.
Method Development/Optimization. O-glycans were
released from 20 pmol of porcine stomach mucin (a well
characterized, commercially available glycoprotein), by dissolv-
ing in SDS and then exchanging SDS for urea in a centrifugal
ﬁlter unit (as for FASP36 and FANGS34). O-Glycans were
released, in the ﬁlter, by treatment with NH4OH. After
collecting and permethylating the glycans, a matrix-assisted
laser desorption/ionization-Fourier transform ion cyclotron
resonance (MALDI-FTICR) mass spectrum was obtained,
revealing expected glycan signals48−50 between m/z 500 and
2214 (Figure S-1), conﬁdently assigned, as mass accuracies for
the majority were below 1 ppm (Table S-1).
A recent publication describes enhanced ﬁlter-aided sample
preparation44 (eFASP), using alternative reagents to those ﬁrst
described by Manza et al.35 and later in FASP by Wisniewski et
al.,36 reporting increased sensitivity and sample recovery for
proteomics. To see whether eFASP sample preparation could
also yield improved results for our glycomics applications,
samples of mucin were prepared for O-glycan release, using
eFASP for SDS solubilization and removal/exchange, to
compare with FASP. After O-glycan release and permethyla-
tion, a MALDI-FTICR mass spectrum was obtained, revealing
expected O-glycans for mucin48 between m/z 500 and 2214.
Data from the two sample preparation methods show the same
O-glycans were released, but better signal-to-noise was
observed for the sample prepared using eFASP reagents,
Figure S-1.
Alkylation in FASP/FANGS is carried out using 50 mM
iodoacetamide in the ﬁlter unit, for 15 min. In comparison, in
eFASP the recommended alkylation step takes 1 h at 37 °C,
with 50 mM iodoacetamide (in the authors’ standard protocol)
or with 4-vinylpyridine (4-VP) (in their express protocol, where
the alkylating reagent is added before the sample is transferred
to the ﬁlter, eliminating a washing step). We investigated the
alkylation step to determine whether it is possible to keep the
reaction time at 15 min, as in FASP/FANGS. Mucin samples
were prepared for O-glycan release using eFASP reagents.
Samples were alkylated for 15 min or 1 h, using iodoacetamide
or 4-VP, and O-glycans were released and permethylated.
Overall, 4-VP treatment gave spectra with better signal-to-noise
than those from samples prepared using iodoacetamide, and
there appeared to be no discernible diﬀerence in the results
following alkylation for 15 min or 1 h (Figure S-2), suggesting
15 min with 4-VP is suitable for our application.
Reducing Incubation Time for O-Glycan Release.
Classic methods for releasing O-glycans generally use
incubation for 16−18 h. In order to reduce the time for glycan
release, sonication in a sonic bath and microwave irradiation
using a laboratory microwave reactor were investigated.
Sonication times of 5, 10, 15, and 20 min were tested to aid
O-glycan release. Glycan signals could be observed after only 5
min of sonication (data not shown), but it was diﬃcult to avoid
the sonic bath temperature rising above 45 °C on sonication for
longer periods. 45 °C was chosen for direct comparison with
overnight incubation and with the intention of avoiding
hydrolysis of labile glycans. Sonicating for 5 min, followed by
holding the sample in the sonic bath for 10 min without
sonicating, and then repeating rounds of sonication/rest
ensured the temperature remained at 45 °C. Using a total of
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20 min sonication interspersed with 40 min rest (a total O-
glycan release time of 1 h) gave glycan proﬁles that were
comparable with those obtained on overnight incubation at 45
°C, Figure S-3. Sonication was thus chosen as the method to
pursue because it is compatible with glycan release in the ﬁlter
unit. When using the microwave reactor, samples had to be
transferred from the ﬁlter unit to a microwave tube and back,
which would incur inevitable sample loss. In addition, because
the sonication was carried out in a sonic bath, multiple samples
can be handled side-by-side, and so the approach is amenable to
handling multiple samples in parallel, in line with the aims of
the developed method.
After optimizing O-glycan release using porcine stomach
mucin, the method was applied to porcine bladder urothelial
cells to demonstrate its application to a cell sample. Samples of
porcine bladder urothelium were prepared for O-glycan release
following our optimized eFASP/FANGS protocol, and O-
glycans were released by treating with NH4OH in the ﬁlter unit
using overnight incubation (16 h) or four separate 5 min
sonications (interspersed with 10 min rests). Glycans were
permethylated, and on obtaining a MALDI-FT-ICR mass
spectrum, O-glycan signals were identiﬁed in both the
overnight incubation and sonication-aided release samples,
between m/z 518 and 1777, conﬁdently assigned based on
mass accuracies (Table S-1). Nonfucosylated/sialylated glycans
were observed at m/z 518, 722, 967, and 1171. Fucosylated
glycans were identiﬁed at m/z 692, 896, 937, 1141, 1315, and
1328 and sialylated glycans were identiﬁed at m/z 879, 1083,
1124, 1154, 1328, 1358, 1485, 1573, 1777, Figure 1. Even those
glycans of low abundance could be readily identiﬁed in the
sonicated sample (m/z 692, 1083, 1358, 1485, 1573, 1777).
The sonication method left labile sialic acid moieties intact and
showed comparable signal-to-noise for each of the sialylated
glycan structures with those in samples prepared using the
overnight method, Figure 1. It was concluded that the
sonication-based method was applicable not only to a simple
soluble glycoprotein standard but also to O-glycans released
from cells.
One-Sample, One-Pot: The N- and O-Glycans. Both N-
and O-glycans are important when studying disease, and so
access to a protocol allowing analysis of the whole glycome
from one sample handled in the same reaction pot is desirable,
especially one based around the use of centrifugal ﬁlters that
enable use of small cell numbers as well as low volumes of
reagents. The workﬂows for releasing N-glycans and O-glycans
were thus combined, to test whether N-glycans and O-glycans
could both be released from the same sample in the same
reaction vessel.
Figure 1.MALDI-FTICR mass spectrum of permethylated O-glycans (ionized as [M + Na]+) released from porcine bladder urothelium using (a) 16
h incubation, (b) 20 min sonication (1 h total release time) at 45 °C. Displayed glycan structures are intended to indicate composition only.
Figure 2. SDS-PAGE analysis of 4 μg of RNase B following FANGS-based sample preparation and subsequent N-glycan release with 37 °C
overnight incubations using PNGase F amounts of 1, 0.3, 0.1, and 0.03 U in a 10 μL volume. Prior to FANGS, the lysis buﬀer contained varying SDS
w/v concentrations of 4%, 2%, and 1% during denaturation.
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Before combining the glycan release protocols, the FANGS
protocol was optimized to enhance the eﬃciency of PNGase F
digestion. Given the critical micelle concentration (CMC) of
SDS is approximately 0.1%, if the SDS used for glycoprotein
extraction is not suﬃciently diluted with urea buﬀer, it would be
expected to form micelles that would be retained by the ﬁlter
membrane due to their size; the resulting levels of residual SDS
could reduce the eﬃciency of PNGase F. The lysis buﬀer used
in FANGS contains 4% SDS, and therefore the 10-fold dilution
described in the FASP and FANGS protocols generates a 0.4%
SDS solution, which is above the CMC. To test whether this
SDS concentration does indeed have an inhibitory eﬀect,
RNase B was denatured in buﬀers with SDS concentrations of
1%, 2%, and 4%. Subsequently, the solution was diluted 20-fold
with urea-Tris buﬀer and washed using a centrifugal
concentrator ﬁlter as in FANGS. The resulting RNase B
solution was then removed from the ﬁlter, divided into equal
sized aliquots, and digested with decreasing amounts of
PNGase F to assess the eﬃciency of cleavage. While the
sample treated with 4% SDS is not fully cleaved even by 1 Unit
PNGase F, reducing the SDS concentration to 2% followed by
20-fold dilution was suﬃcient to require as little as 0.003 Unit
enzyme for full cleavage (Figure 2).
The next aim was to test the use of considerably reduced
levels of PNGase F in the modiﬁed FANGS procedure to
generate good quality glycan mass spectra. This is important for
medium throughput applications in which the cost of PNGase
F could become prohibitive. RNase B was denatured in a
solution containing 2% SDS (a detergent amount suﬃcient
when using a puriﬁed soluble protein rather than a cell
suspension). When FANGS was performed following 10-fold
dilution, no observable glycan peaks were obtained following
digestion using 3 mUnits of enzyme. In contrast, the same
amount of enzyme used with FANGS following 20-fold dilution
of the SDS produced good glycan peaks (Figure 3). The
spectrum shows only the most abundant N-glycan signals due
to the more than 2000-fold lower PNGase F level than in the
standard FANGS protocol.34 The conclusion is that in the case
of cell extracts, where 4% SDS is needed for full solubilization
of the lipid and protein content, 40-fold dilution of the SDS
solution should be used to achieve optimal PNGase F activity.
Porcine bladder urothelium was treated using the optimized
sample preparation workﬂow based on eFASP, including the
1:40 dilution, and then treated with PNGase F for 16 h at 37
°C in the ﬁlter unit. Following incubation, the ﬁlter was
centrifuged to collect the released N-glycans. The ﬁlter was
transferred to a clean collection tube and O-glycans were
subsequently released with NH4OH treatment, aided by 20 min
sonication (4 × 5 min bursts, interspersed with 4 × 10 min
rests) at 45 °C. O-Glycans were retrieved on centrifugation of
the ﬁlter unit. N- and O-Glycans were permethylated. N-
Glycans were observed from m/z 967 to 2966, corresponding
mainly to oligomannose species, with some complex type N-
glycans, some of which were sialylated and others fucosylated.
O-Glycans were observed between m/z 518 and 1777 (Figure
4), the same as for the urothelial O-glycan sample from which
N-glycans had not previously been released. Focusing on m/z
1500−3000 in the O-glycan spectrum, it is clear that there are
no signals corresponding to N-glycans, suggesting that all the
N-glycans were washed out of the ﬁlter before O-glycan release.
However, there are signals observed in both the N- and the O-
glycan spectra at m/z 967, m/z 1141, and m/z 1171. Although
these signals could formally be due to carry over of N-glycans
into the O-glycan sample, these three signals are observed in a
spectrum of O-glycans that had been prepared without
previously releasing N-glycans. This, together with the fact
that none of the other more abundant N-glycans are observed
contaminating the O-glycan sample, suggests that it is unlikely
that the m/z 967, 1141, and 1171 signals derive from N-glycan
carryover, and this was demonstrated on product ion analysis of
these species in the two glycan fractions, Figures S-4−S-6.
To show that the developed method can be used as a truly
one pot method to study glycans and protein, after both the N-
and O-glycans had been released and isolated, the remaining
protein in the ﬁlter unit was treated with trypsin. The tryptic
peptides were collected in the ﬁltrate after centrifugation and
analyzed by LC−MS/MS. Mascot searching matched 5005
peptides and identiﬁed 1301 proteins, FDR 1% (Supporting
Information). These results were compared with those from a
Figure 3. Positive ion mode MALDI mass spectra of permethylated FANGS-released N-glycans from 40 μg of RNase B using 0.003 U PNGase F
and 2% SDS containing lysis buﬀer prior to FANGS: (a) using 10× dilution in urea-buﬀer following lysis and (b) using 20× dilution in urea-buﬀer
following lysis.
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porcine urothelium sample treated with trypsin without prior
removal of the glycans. Mascot searching matched 1348
proteins and 5323 peptides, FDR 1% (Supporting Informa-
tion). Proteins identiﬁed were similar across the two sets of
data, with 848 proteins the same in the two sets of data.
Although this experiment was only carried out once, as a proof
of concept, the results suggest that the proteomic analysis is not
substantially compromised by prior glycan release.
Application to Study of Cultured Cells. MSCs are adult
stem cells that have the ability to diﬀerentiate into adipocytes,
chondrocytes, and osteoblasts to make fat, cartilage, or bone
tissue.51,52 The ability to diﬀerentiate into diﬀerent cell types
means there is a potential use of MSCs in regenerative
medicine,53,54 for use in cell replacement55 and in tissue
engineering.56 Their ability to diﬀerentiate into diﬀerent
lineages also provides an excellent opportunity to study the
connections between glycan biosynthesis and cellular diﬀer-
entiation. The potential for genetic manipulation within the
immortalised primary lines has also the potential to generate
cellular models of CDGs, for example, by introducing COG
mutations to observe diﬀerences in glycan proﬁles.
MSC lines used in this study have been immortalized using
human telomerase reverse transcriptase, designated hTERT-
MSCs,45 and undergone single cell cloning. This removes
heterogeneity seen in primary cell populations for a more
reliable comparison of changes in glycosylation across sample
Figure 4. MALDI-FTICR mass spectrum of permethylated glycans released from porcine bladder urothelium, ionized as [M + Na]+: (a) N-glycans
released before O-glycans and (b) O-glycans released after N-glycans in the same ﬁlter unit from the same sample. The displayed glycans indicate
composition only.
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replicates. Two hTERT-MSC cell lines have been used, Y201
and Y101, to allow comparison of two lines with somewhat
diﬀerent functional properties. These cell lines have diﬀerent
abilities to diﬀerentiate; while Y201 cells can form all three
MSC-derived lineages, Y101 cells have limited adipogenic
capacity but can readily form osteoblasts.
Proﬁling of N-glycans of MSCs has been investigated and
reported.57,33 N-glycan proﬁling of the immortalized cell lines
Y201 and Y101 has been reported by Wilson and colleagues.58
What is currently lacking is analysis of the O-glycan proﬁle of
such cells to determine how the O-glycan proﬁle changes after
diﬀerentiation or genetic modiﬁcation of these cell lines.
The developed O-glycan release method was applied to wild-
type (WT) Y201 and Y101 MSCs to test the procedure with
cultured cell samples. Cells were grown in a 10 cm culture dish,
before being harvested. O-Glycans were released and
permethylated. O-Glycans were identiﬁed from their character-
istic signals at m/z 518, 722, 879, 967, 1083, 1141, 1171, 1240,
and 1328 for the Y101 cell line and at m/z 518, 722, 879, 926,
967, 1083, 1141, 1240, 1328, and 1345, for the Y201 cell line,
Figure S-7. The signals were conﬁdently assigned based on their
Figure 5. O-glycan proﬁles of Y201 and Y101 WT MSCs. Relative abundance expressed as a percentage of each glycan signal compared to a spiked
internal standard signal. Statistical analysis was carried out using one-way ANOVA with Holm Sidak posthoc test (n = 5) (* for P = <0.05, ** for P =
<0.01 and *** for P = <0.0001). Glycan structures intended to indicate composition only.
Figure 6. Comparing O-glycan proﬁles of Y101 WT MSCs with Cog4KD MSCs. Relative abundance calculated by expressing each glycan signal as a
percentage of the spiked internal standard signal. Statistical analysis was carried out using a one-way ANOVA with Holm Sidak posthoc test (n = 5)
(* for P = <0.05, ** for P = <0.01). Glycan structures intended to indicate composition only.
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mass accuracies, which were below 1 ppm (Table S-3). Samples
were spiked with an internal standard, deuteropermethylated
maltotetraose, to enable relative quantiﬁcation of the glycans to
see if there was any diﬀerence in glycan relative abundances
between the two cell lines. On comparing the resulting glycan
proﬁles, three O-glycans were signiﬁcantly higher in relative
abundance in the Y201 than the Y101 cell line. These were
Hex2HexNAc1 (P = 0.0028**), Hex3HexNAc1 (P =
<0.0001***), and Hex2HexNAc2Fuc1 (P = <0.0001***).
Statistical analysis was carried out using a one-way ANOVA
with Holm Sidak posthoc test (n = 5) (* for P = <0.05, ** for P
= <0.01, and *** for P = <0.0001), Figure 5. These diﬀerences
in the abundance of O-glycans could perhaps be involved in the
diﬀering potentials of the two cell lines to diﬀerentiate. The
glycan identiﬁed containing three hexose residues (presumably
galactose) attached to the GalNAc core is an unusual structure,
previously identiﬁed59 on calf thyroid membrane glycoprotein
GP-3.
Since the developed O-glycan release method worked well
on the wild-type MSC cell lines, Cog4KD MSCs were also
analyzed. These cells are derived from the Y101 cell line by
knocking down the Cog4 subunit of the COG complex using
stable expression of a Cog4 speciﬁc shRNA (K. Wilson, P.
Genever, and D. Ungar, unpublished data). O-Glycans were
released from Cog4KD MSCs to see whether there were any
changes to the O-glycan proﬁle when compared with wild-type
cells. O-Glycans were identiﬁed at m/z 518, 722, 879, 967, and
1328, Figure S-8, conﬁdently assigned based on their mass
accuracies, which were all below 1 ppm (Table S-4) and
intensities compared again using the approach of spiking with
deuteromethylated maltotetraose.
For glycan structures Hex2HexNAc1 and Hex2HexNAc2, both
presumably bearing a terminal galactose, there is an increase in
the relative abundance in the Cog4KD cells, compared with the
wild-type cells, Figure 6. This could be attributed to loss of
ability to transfer a sialic acid to galactose in Hex2HexNAc2,
shown by an absence of Hex2HexNAc1NeuAc1, a signiﬁcant
change when compared with the wild-type cells (P = 0.0962*).
However, there is a signiﬁcant increase in abundance of
Hex1HexNAc1NeuAc1, (P = 0.0069**). The large increase in
abundance of Hex1HexNAc1NeuAc1 could be due to the
reduced ability to transfer a second sialic acid to the growing
glycan chain, shown by the absence of Hex1HexNAc1NeuAc2 in
the Cog4KD sample, a change compared with the WT sample
that is signiﬁcant (P = 0.0028**). There is also a loss of the
fucosylated O-glycan, Hex2HexNAc2Fuc1, although this glycan
is only relatively low abundance in the WT sample.
A study by Reynders et al. analyzed N-glycans in CDG
patient cells with a mutation to Cog4, resulting in defective
Cog4 protein, and found there was a decrease in sialylated N-
glycans.60 It has also been reported that in disorders aﬀecting
both N- and O-glycans, sialylation is decreased in both glycan
types.8 One study analyzed O-glycans, by MS, from serum and
plasma samples of patients with mutations to Cog4 and Cog7
and found decreased sialylation in both. The ﬁrst described
example of an inborn error in metabolism aﬀecting both N- and
O-glycosylation reported a decrease in sialylated N- and O-
glycans, where the O-glycosylation status was determined by
analyzing apoplioprotein C-III (a protein which is only O-
glycosylated), using isoelectric focusing.61 Moreover, N-glycan
proﬁling as well as PNA-lectin staining of the Cog4KD cells
suggested a defect in sialylation (K. Wilson, P. Genever, and D.
Ungar, unpublished data). PNA binds to terminal Gal-GalNAc,
and since binding of this lectin only occurs for unsialylated
structures, the increase in binding for PNA could suggest a
decrease in sialylated structures. All the evidence described
above adds conﬁdence to the results from this O-glycan
proﬁling, using only a small number (∼1 million) of cultured
cells.
Since the developed one-pot method was successfully used to
analyze porcine bladder urothelium, the MSC wild-type and
Cog4KD samples, that had previously had the O-glycans
removed were subsequently treated with PNGase F to release
the N-glycans. Released N-glycans were permethylated and
spiked with the internal standard to carry out relative
quantiﬁcation of the N-glycans. N-glycans were identiﬁed
between m/z 967 and m/z 3054 for the WT MSCs, showing
the presence of both oligomannose and complex-type N-
glycans. For Cog4KD MSCs, N-glycans were identiﬁed
between m/z 967 and 2396, also showing the presence of
both oligomannose and complex-type N-glycans, Figure S-9.
For both samples, oligomannose type N-glycans appear to be
most abundant, but the abundance of these glycans is lower in
the Cog4KD sample. There is an increase in abundance of the
glycans at lower masses (HexNAc2Hex2, HexNAc2Hex2Fuc1,
and HexNAc2Hex3) for the Cog4KD. Sialylated glycans present
in WT MSCs are not detected in the Cog4KD sample. There is
also a decrease in abundance of complex-type glycans that
contain a terminal hexose (presumably galactose). These results
are in agreement with previous results generated by Wilson and
colleagues, who carried out N-glycan proﬁling of Y101 MSCs58
and Cog4KD MSCs (K. Wilson, P. Genever, and D. Ungar,
unpublished data) as well as results described by Reynders et
al.,60 which showed a decrease in sialylated N-glycans in Cog4
CDG patients. Interestingly, the current data suggest that the
Cog4KD cells contain fewer N-glycans overall than the WT.
■ CONCLUSIONS
A simple method has been developed for release and isolation
of O-glycans from glycoproteins from whole cell lysates. The
O-glycan release can be carried out in 1 h with the aid of
sonication, not previously applied to the release of glycoprotein
glycans; this oﬀers a signiﬁcant improvement on traditional
incubation times of 16−18 h. In addition, both N- and O-
glycans can be studied from one sample, in the same ﬁlter unit,
by combing the established protocol for ﬁlter-aided N-glycan
separation, optimized for enhanced PNGase F eﬃciency, with
subsequent O-glycan release (or vice versa) on a realistic
number of cultured cells (1 × 106). Furthermore, the method
allows subsequent proteomic analysis of the protein remaining
after glycan release. By virtue of its applicability to medium
throughput studies, our approach oﬀers a simple way to assess
the often subtle changes to glycan proﬁles seen in diﬀer-
entiation and disease progression, in a statistically robust way
using biological replicates.
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